Clinical trials / NCT06388200
NCT06388200Phase 3Active not recruiting

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Study sponsor: Ocugen

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2027-02-12Estimated
Enrollment · participants140Actual
Source updated2026-07-31Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Number of participants with change in functional vision in the study eye of RP subjects as assessed by LDNA Measure: Number of participants with change in functional vision in the study eye in Gene Agnostic group as assessed by LDNA

+ After

Measure: Change in functional vision from baseline to week 52 in pooled analysis when study eyes in treatment group were compared to study eyes in untreated control

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

150 participants (planned)

+ After

140 participants (actual)

Primary completion date changed

− Before

31 Dec 2026

+ After

12 Feb 2027

Check registry source

· 1 field changed

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source